'+
'| • '+heading+' |
| '+
''+
' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("selfdirectedinvestor.com") > 0) || (ref.indexOf("128.241.244.123") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("marketnewsvideo.mobi") > 0) || (ref.indexOf("206.71.145.70") > 0) || (ref.indexOf("206.71.145.73") > 0) || (ref.indexOf("206.71.145.76") > 0) || (ref.indexOf("selfdirectedinvestor.mobi") > 0) || (ref.indexOf("google.") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
| •\; Detailed Quotes - MRK | \n'); } if (allow) { document.write('Saturday, May 4, 9:21 AM\n'); } if (allow) { document.write(' |
 | |
\n'); } if (allow) { document.write('
| Look under \'\'More Info\'\' for further information. At least 20 min. delay. | \n'); } if (allow) { document.write('\; | \n'); } if (allow) { document.write('
| \n'); }
if (allow) { document.write(' Merck & Company Inc New (NYSE: MRK)\n'); }
if (allow) { document.write(' \n'); } if (allow) { document.write('More Info: \n'); } if (allow) { document.write('chart \;comp profile \;stock screen \;news \;www.merck.com  \n'); }
if (allow) { document.write(' ValueForum rating\n'); }
if (allow) { document.write(' \n'); }
if (allow) { document.write('\n'); }
if (allow) { document.write(' | \n'); }
if (allow) { document.write('||||||
| Last Trade 4:00 p.m. - 127.51 | \n'); }
if (allow) { document.write('Change \;0.75 ( \;0.58%) | \n'); }
if (allow) { document.write('Trades Today 78,013 | \n'); }
if (allow) { document.write('Day\'s Volume 6,221,854 | \n'); }
if (allow) { document.write('|||
| Beta 0.5068 | \n'); }
if (allow) { document.write('Day\'s Range 127.18 - 128.48 | \n'); }
if (allow) { document.write('Prev Close 128.26 | \n'); }
if (allow) { document.write('Open 128.01 | \n'); }
if (allow) { document.write('52 Wk Range 99.14 - 133.10 | \n'); }
if (allow) { document.write('||
| EPS 0.14 | \n'); }
if (allow) { document.write('PE 910.86 | \n'); }
if (allow) { document.write('Quarterly Div/Shr 0.77 | \n'); }
if (allow) { document.write('Ex-Div 03/14/24 | \n'); }
if (allow) { document.write('Yield 2.42% | \n'); }
if (allow) { document.write('Shares Out. 2.53B | \n'); }
if (allow) { document.write('Market Cap. 322.99B | \n'); }
if (allow) { document.write('
| \n'); } if (allow) { document.write(' \; \;•\; \;1 Year Stock Performance:\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write('||||||
| \n'); }
var SC_width= "558";
var SC_height= "279";
var SC_clientId = "sdi";
var SC_type= "line";
var SC_period = "1y";
var SC_chartBackgroundColor= "FFFFFF";
var SC_gridLocation= "background";
var SC_labelSide = "left";
var SC_gridBackgroundColor= "EEEEEE";
var SC_gridColor= "B0B1A5";
var SC_axisColor= "000000";
var SC_symbols= "MRK";
var SC_showHighsLows= "no";
var SC_movingAverages= "no";
var SC_movingAverageColors = "FF8800,009900";
var SC_symbolLabels= "yes";
var SC_lineThicknesses= "1";
var SC_lineColors= "022061,AD0000,00FF00,DE6E00,ACA715,3C86AC,AC009A,FF0000,07AD80,1400AC";
var SC_showPrevClose= "no";
var SC_prevCloseColor= "990000";
var SC_fillBelowLine = "yes";
var SC_fillColor= "E5E6C5";
var SC_fillColor2= "FF0000";
var SC_smoothChart= "yes";
var SC_smoothFonts= "yes";
var SC_fontFace= "Arial";
var SC_fontSize= "2";
var SC_labelColor= "1E116D";
var SC_bottomLabels= "";
var SC_beforeLeftLabels= escape('');
var SC_afterLeftLabels= escape('');
var SC_leftLabelsEvery= "12";
var SC_leftBuffer= "35";
var SC_rightBuffer= "55";
var SC_bottomBuffer= "25";
var SC_bottomTableHeight= "30";
var SC_showVolumeTable= "yes";
var SC_showLegendTable = "no";
var SC_volumeColor= "1E116D";
document.write(' | \n'); }
if (allow) { document.write('||||||
| \n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' | \;symbol lookup \; | \n'); } if (allow) { document.write('\; Find more stocks like \; | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' |
| 5/1 - 7:15 AM \; \; | \n'); } if (allow) { document.write('Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | \n'); } if (allow) { document.write('
| 4/29 - 9:00 AM \; \; | \n'); } if (allow) { document.write('Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults | \n'); } if (allow) { document.write('
| 4/25 - 10:57 AM \; \; | \n'); } if (allow) { document.write('Dow Movers: IBM, MRK [VIDEO] | \n'); }
if (allow) { document.write('
| 4/25 - 6:30 AM \; \; | \n'); } if (allow) { document.write('Merck Announces First-Quarter 2024 Financial Results | \n'); } if (allow) { document.write('
| 4/19 - 7:06 AM \; \; | \n'); } if (allow) { document.write('Health Canada Approves KEYTRUDA®\; as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy | \n'); } if (allow) { document.write('
| 4/19 - 7:05 AM \; \; | \n'); } if (allow) { document.write('Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy | \n'); } if (allow) { document.write('
| 4/4 - 6:45 AM \; \; | \n'); } if (allow) { document.write('Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer | \n'); } if (allow) { document.write('
| 4/3 - 8:00 AM \; \; | \n'); } if (allow) { document.write('REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer | \n'); } if (allow) { document.write('
| 4/1 - 6:45 AM \; \; | \n'); } if (allow) { document.write('Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 | \n'); } if (allow) { document.write('
| 3/28 - 9:16 AM \; \; | \n'); } if (allow) { document.write('How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together | \n'); } if (allow) { document.write('
| 3/28 - 6:45 AM \; \; | \n'); } if (allow) { document.write('European Commission Approves Merck\'s KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults | \n'); } if (allow) { document.write('
| 3/27 - 10:20 AM \; \; | \n'); } if (allow) { document.write('S&P 500 Movers: CCL, CTAS [VIDEO] | \n'); }
if (allow) { document.write('
| 3/27 - 10:19 AM \; \; | \n'); } if (allow) { document.write('Dow Movers: V, MRK [VIDEO] | \n'); }
if (allow) { document.write('
| 3/26 - 6:21 PM \; \; | \n'); } if (allow) { document.write('FDA Approves Merck\'s WINREVAIR™\; (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO Group 1) | \n'); } if (allow) { document.write('
| 3/26 - 9:31 AM \; \; | \n'); } if (allow) { document.write('Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region | \n'); } if (allow) { document.write('
| |
| more news | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('
| \n'); }
if (allow) { document.write('|
 | \n'); }
if (allow) { document.write(' \n'); } if (allow) { document.write(' \n'); } if (allow) { document.write(' Private-label branded pages powered by TickerTech.com. \n'); } if (allow) { document.write(' Copyright ©\; 2024 Ticker Technologies Inc., \n'); } if (allow) { document.write('All Rights Reserved. Quote data is at least 20 minutes delayed. \n'); } if (allow) { document.write('NYMEX/COMEX data is at least 30 minutes delayed. Please read other important \n'); } if (allow) { document.write(' disclaimer information.\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write('
If you reached this page'+
' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+
' paying client. For pricing information please visit our products page, email '+
' services@tickertech.com, or give us a call at 1-866-515-2082.'+
' '+
'